iShares Biotechnology ETF (IBB) Stock
Diversified biotechnology fund tracking drug development companies. Here's the price, business snapshot, and what's worth knowing about iShares Biotechnology ETF in October 2026.
The iShares Biotechnology ETF (IBB) offers investors diversified access to the dynamic biotechnology sector. As an exchange-traded fund, it tracks the performance of companies involved in medical research, drug development, and biotech innovation. With 249 holdings and net assets of USD 10.45 billion, IBB provides broad exposure to this capital-intensive industry. It carries an expense ratio of 0.44% and a modest dividend yield of 0.16%, reflecting the sector's focus on reinvestment for growth rather than income. Investors should note that biotechnology stocks can be highly volatile, driven by regulatory approvals and clinical trial outcomes. This ETF suits those seeking general exposure to healthcare innovation who understand that values can rise and fall significantly.
About This Stock
ISHARES TRUST ISHARES BIOTECHNOLOGY ETF
IBB
Current Price
$208.28
Potential 12 Month Profit
N/A
Sector
N/A
Industry
N/A
Ticker
IBB
Market Cap
N/A
Potential 12 Month Profit
N/A
Sector
N/A
Industry
N/A
Sixth Month Growth Performance
Stock Performance Snapshot
Dividend
ISHARES TRUST ISHARES BIOTECHNOLOGY ETF does not pay a dividend, which might be due to reinvesting profits to fuel growth. If you invested $1000 you would be paid $0 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Broad Biotech Exposure
This ETF provides access to 249 companies, offering a way to track the biotechnology sector's collective movements without the risk of picking a single stock. Though performance can vary significantly, it reflects the diverse landscape of medical innovation.
Focus on Innovation
As many biotech firms reinvest earnings into research rather than paying dividends, IBB aligns with companies that are actively developing new therapies. Investors might watch for breakthroughs and clinical trial results that could influence share prices.
Regulatory & Sector Trends
Biotechnology values are often sensitive to regulatory approvals and healthcare policy. The ETF allows you to stay informed about these sector-wide trends and how they might impact the industry's growth outlook. Remember that these factors can also pose risks to returns.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
